www.fdanews.com/articles/179152-ferring-pharmaceuticals-launches-noqdirna-in-uk
Ferring Pharmaceuticals Launches Noqdirna in UK
November 4, 2016
Ferring Pharmaceuticals announced the UK launch of Noqdirna, which is the only licensed treatment for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults, including those over 65.
Nocturia, the need to wake at night to pass urine, impacts around 8.63 million people in the UK.
Although there are several reasons why people may be affected by nocturia, the night-time overproduction of urine — known as nocturnal polyuria — is a contributor in up to 88 percent of cases.